Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study 71st Annual Scientific Meeting of the American-College-of-Rheumatology/42nd Association-of-Rheumatology-Health-Professionals Genovese, M., McKay, J., Nasonov, E., Myster, E., da Silva, N., Alecock, E., Woodworth, T., Gomez-Reino, J. WILEY-LISS. 2007: 4309–10
View details for Web of Science ID 000251781200185